Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.

Smith RE Jr, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J.

Br J Cancer. 2003 Jun 16;88(12):1851-8.

2.

Darbepoetin alfa: in patients with chemotherapy-related anaemia.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(11):1067-74; discussion 1075-7. Review.

PMID:
12749734
3.

Phase III clinical trials with darbepoetin: implications for clinicians.

Glaspy J.

Best Pract Res Clin Haematol. 2005;18(3):407-16. Review.

PMID:
15792914
4.

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly.

Eur J Cancer. 2007 Jan;43(2):258-70. Epub 2006 Dec 19. Review.

PMID:
17182241
5.

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.

Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C.

Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. Review.

6.
7.

Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin.

Keller F, Ludwig U, Czock D.

Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):139-47. doi: 10.1517/17425255.2015.989832. Epub 2014 Dec 3. Review.

PMID:
25466552

Supplemental Content

Support Center